T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Tanta University
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
Peking University Cancer Hospital & Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BicycleTx Limited
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Royal Marsden NHS Foundation Trust
Hebei Medical University Fourth Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Canadian Cancer Trials Group
National Cancer Institute (NCI)
Providence Health & Services
Astellas Pharma Inc
National Cancer Institute (NCI)
Pfizer
Stanford University
Washington University School of Medicine
National Cancer Institute (NCI)
University of Wisconsin, Madison
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nantong Bencao Quadriga Medical Technology Co. Ltd.
ALX Oncology Inc.
UNC Lineberger Comprehensive Cancer Center
Xijing Hospital
UNC Lineberger Comprehensive Cancer Center
Hoffmann-La Roche
Odense University Hospital
Abramson Cancer Center at Penn Medicine
Jazz Pharmaceuticals
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University of California, San Diego
Sun Yat-sen University
National Cancer Institute (NCI)
Hoosier Cancer Research Network
Fudan University
Bayer
Damanhour University
Alliance for Clinical Trials in Oncology
MedSIR
Henan Cancer Hospital
Hoffmann-La Roche